Intervacc AB (IVACC) - Total Liabilities

Latest as of September 2025: Skr18.76 Million SEK ≈ $2.02 Million USD

Based on the latest financial reports, Intervacc AB (IVACC) has total liabilities worth Skr18.76 Million SEK (≈ $2.02 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Intervacc AB annual equity growth to track the company's year-over-year net asset growth rate.

Intervacc AB - Total Liabilities Trend (2013–2024)

This chart illustrates how Intervacc AB's total liabilities have evolved over time, based on quarterly financial data. See Intervacc AB (IVACC) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Intervacc AB Competitors by Total Liabilities

The table below lists competitors of Intervacc AB ranked by their total liabilities.

Company Country Total Liabilities
Mister Spex SE
F:MRX
Germany €102.07 Million
Grupo Concesionario del Oeste SA
BA:OEST
Argentina AR$134.77 Billion
Yufo Electronics Co Ltd
TWO:6194
Taiwan NT$377.76 Million
E& Corporation CO. LTD
KQ:066980
Korea ₩95.85 Billion
Fractal Gaming Group AB
ST:FRACTL
Sweden Skr190.80 Million
Equus Energy Ltd
AU:EQU
Australia AU$2.18 Million
Renishaw PLC
LSE:RSW
UK GBX199.53 Million
Asian Pac Holdings Bhd
KLSE:4057
Malaysia RM1.12 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Intervacc AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Intervacc AB market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.00 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.06 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Intervacc AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Intervacc AB (2013–2024)

The table below shows the annual total liabilities of Intervacc AB from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 Skr24.99 Million
≈ $2.69 Million
+15.26%
2023-12-31 Skr21.68 Million
≈ $2.33 Million
+45.74%
2022-12-31 Skr14.88 Million
≈ $1.60 Million
-29.63%
2021-12-31 Skr21.14 Million
≈ $2.28 Million
+19.63%
2020-12-31 Skr17.67 Million
≈ $1.90 Million
+2.48%
2019-12-31 Skr17.25 Million
≈ $1.86 Million
+40.97%
2018-12-31 Skr12.23 Million
≈ $1.32 Million
-17.03%
2017-12-31 Skr14.74 Million
≈ $1.59 Million
-55.95%
2016-12-31 Skr33.47 Million
≈ $3.60 Million
+17.72%
2015-12-31 Skr28.44 Million
≈ $3.06 Million
-46.08%
2014-12-31 Skr52.74 Million
≈ $5.68 Million
+4143.19%
2013-12-31 Skr1.24 Million
≈ $133.76K
--

About Intervacc AB

ST:IVACC Sweden Biotechnology
Market Cap
$44.89 Million
Skr417.16 Million SEK
Market Cap Rank
#22256 Global
#420 in Sweden
Share Price
Skr1.22
Change (1 day)
-3.62%
52-Week Range
Skr0.61 - Skr1.39
All Time High
Skr89.40
About

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more